Literature DB >> 2613280

Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice.

M E Andrew1, B E Coupar, D B Boyle.   

Abstract

Intravenous (i.v.) immunization of mice with recombinant vaccinia viruses stimulated the highest antibody and cytotoxic T lymphocyte (CTL) responses when i.v., intraperitoneal (i.p.), intranasal (i.n.), footpad (f.p.) and tail scarification (t.s.) routes were compared. Intraperitoneal immunization of mice resulted in high CTL activity, but low antibody responses. Antibody levels after i.n., f.p., and t.s. immunization were slightly lower than following i.v. immunization. Although very low levels of CTL primary activity were stimulated by i.n. or f.p. inoculation of recombinant vaccinia virus, levels of secondary CTL activity after in vitro restimulation of splenocytes were as high as those seen from i.v. immunized splenocytes. The effect of the thymidine kinase (TK) phenotype of the virus also was examined. Wildtype (TK positive) viruses replicated to a higher titre in vivo and stimulated higher antibody and CTL responses than a TK negative recombinant virus. A recombinant virus that expressed the TK gene from herpes simplex virus at a low level was intermediate between wildtype and TK negative virus, both in virus replication in vivo and in immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2613280     DOI: 10.1038/icb.1989.48

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  9 in total

1.  Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

Authors:  K H Leong; A J Ramsay; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

2.  Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.

Authors:  R S Chamberlain; M W Carroll; V Bronte; P Hwu; S Warren; J C Yang; M Nishimura; B Moss; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

3.  Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.

Authors:  M M Gherardi; J C Ramírez; M Esteban
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene.

Authors:  Pavel Gabriel; Katarina Babiarova; Kamila Zurkova; Jitka Krystofova; Petr Hainz; Luda Kutinova; Sarka Nemeckova
Journal:  Viral Immunol       Date:  2012-10       Impact factor: 2.257

Review 5.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03

6.  Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.

Authors:  Fatema A Legrand; Paulo H Verardi; Leslie A Jones; Kenneth S Chan; Yue Peng; Tilahun D Yilma
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 7.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

8.  Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus.

Authors:  Anuja Mathew; Joel O'Bryan; William Marshall; Girish J Kotwal; Masanori Terajima; Sharone Green; Alan L Rothman; Francis A Ennis
Journal:  PLoS One       Date:  2008-10-02       Impact factor: 3.240

9.  Virulence in murine model shows the existence of two distinct populations of Brazilian Vaccinia virus strains.

Authors:  Jaqueline Maria Siqueira Ferreira; Betânia Paiva Drumond; Maria Isabel Maldonado Coelho Guedes; Marcelo Antônio Pascoal-Xavier; Camila Megale Almeida-Leite; Rosa Maria Esteves Arantes; Bruno Eduardo Fernandes Mota; Jônatas Santos Abrahão; Pedro Augusto Alves; Fernando Meireles Oliveira; Paulo César Peregrino Ferreira; Cláudio Antônio Bonjardim; Zélia Inês Portela Lobato; Erna Geessien Kroon
Journal:  PLoS One       Date:  2008-08-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.